← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy

nivolumab plus ipilimumab · Bristol Myers Squibb

FDA approvalNew dosing regimenNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Nivolumab 360 mg every three weeks with ipilimumab 1 mg/kg every six weeks for the existing first-line metastatic NSCLC indication with PD-L1 at least 1% and no EGFR or ALK genomic aberrations.

LAMPGEN ANALYSIS

Why it matters

This action adds a fixed nivolumab schedule to the established dual-checkpoint regimen.

What research teams should watch

Coordinate the three- and six-week dosing intervals and distinguish this regimen from combinations with chemotherapy.

PRIMARY RECORDS

Sources